COX-2 Expression Does Not Predict Biochemical Failure in Patients Treated with Salvage Radiation Therapy for Prostate Cancer

2011 ◽  
Vol 81 (2) ◽  
pp. S410-S411
Author(s):  
K.S. Tzou ◽  
S.J. Buskirk ◽  
M.G. Heckman ◽  
A.S. Parker ◽  
V. Patel ◽  
...  
2017 ◽  
Vol 121 (3) ◽  
pp. 365-372 ◽  
Author(s):  
Vasu Tumati ◽  
William C. Jackson ◽  
Ahmed E. Abugharib ◽  
Ganesh Raj ◽  
Claus Roehrborn ◽  
...  

2015 ◽  
Vol 5 (1) ◽  
pp. 79-85
Author(s):  
Nicholas George Zaorsky ◽  
Tianyu Li ◽  
Aruna Turaka ◽  
David Y. T. Chen ◽  
Eric M. Horwitz ◽  
...  

2013 ◽  
Vol 2 (3) ◽  
pp. 309-314
Author(s):  
Michael G. Heckman ◽  
Katherine S. Tzou ◽  
Alexander S. Parker ◽  
Thomas M. Pisansky ◽  
Steven E. Schild ◽  
...  

2016 ◽  
Vol 34 (2_suppl) ◽  
pp. 127-127
Author(s):  
Suneal Gopal Peddada ◽  
Craig Oliver ◽  
Angela Phelps ◽  
Steven H. Stokes ◽  
Jarrod Bartlett Adkison

127 Background: Prostate Specific Antigen (PSA) values post-prostatectomy are used as an indication for salvage radiation therapy. It has been suggested that initiation of therapy at lower PSA values lead to better outcomes. This study investigates outcomes of salvage radiation therapy at specific PSA thresholds. Methods: One hundred two prostate cancer patients were treated with salvage radiotherapy at our institution with curative intent, 19 of whom had Gleason score ≤6, 52 of whom had Gleason 7, and 31 with Gleason ≥8. Median follow-up after radiotherapy was 51 months. The median PSA prior to salvage radiotherapy was 0.33 ng/mL, and the median time from prostatectomy to radiotherapy was 24.6 months. Positive margins were identified in 52 patients, and perineural invasion was positive in 83. The median dose delivered was 64.8 Gy. Results: The 5-year actuarial freedom from biochemical failure rates for NCCN low, intermediate, and high risk groups were 100%, 77%, and 62%, p=0.2449. The 5-year actuarial freedom from biochemical failure rates for Gleason score ≤6, Gleason 7, and Gleason ≥8 patients were 87%, 72%, and 49%, p=0.0187. Patients with pre-radiotherapy PSA ≤0.5 ng/mL had better 5-year biochemical control relative to patients with higher pre-radiotherapy PSA, 76% versus 51%, p=0.0211. The pathological margin status did not predict for biochemical control after salvage radiation across the different Gleason grades. Very few interval biochemical failures are observed after the 5-year point of follow-up. The 5-year overall survival for the entire cohort is 92%, with prostate cancer specific survival of 96%. Conclusions: Salvage radiotherapy demonstrated favorable efficacy with durable PSA control and few failures 5 years post radiation. Initiation of salvage radiotherapy for PSA ≤0.5 ng/mL demonstrated improved biochemical control, supporting the adoption of early referral to radiation oncology once post-prostatectomy biochemical failure is identified. [Table: see text]


Sign in / Sign up

Export Citation Format

Share Document